drugset
drugset / Trial / NCT00936520

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

NCT00936520 ↗

Phase 1 Terminated 30 enrolled Johns Hopkins University SARcode Bioscience · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects undergoing elective vitrectomy when treated with escalating concentrations of the study drug for approximately 1 week.

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lifitegrast Unknown 0.1 % Topical
Subject Lifitegrast Unknown 1 % Topical
Subject Lifitegrast Unknown 5 % Topical

Indications

diabetic macular edema